6 completed, 4 terminated, 2 unknown, 1 active not recruiting. 7 Phase 2, 4 Phase 1, 2 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow glucarpidase: new trials by email Literature Review of glucarpidase trials Research Report on glucarpidase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma Glucarpidase, Methotrexate (MTX) - Primary Central Nervous System Lymphoma | Phase 1 | Unknown | Assistance Publique - Hôpitaux de Paris | 18 | 2022-09-15 | 2022-10-25 |
| Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate High-dose methotrexate, Glucarpidase - Acute Kidney Injury, Drug Toxicity | Unknown | Protherics Medicines Development Limited | 1000 | 2022-04-01 | 2024-05-10 | |
| Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS Glucarpidase 1000 UNT [Voraxaze] - Diffuse Large B-Cell Lymphoma, Drug Toxicity | Phase 2 | Terminated | Fundacion CRIS de Investigación para Vencer el Cáncer | 3 | 2021-07-19 | 2024-05-13 |
| HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma Glucarpidase - Lymphoma | Phase 2 | Suspended | Fox Chase Cancer Center | 3 | 2021-04-16 | 2024-03-22 |
| Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma Glucarpidase, Quality-of-Life Assessment - Osteosarcoma | Early Phase 1 | Completed | OHSU Knight Cancer Institute | 11 | 2019-03-27 | 2026-07-07 |
| LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma Methotrexate, Rituximab, leucovorin - Central Nervous System Lymphoma | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 58 | 2018-11-14 | 2026-04-15 |
| High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma glucarpidase, leucovorin - Osteosarcoma | Phase 2 | Terminated | BTG International Inc. | 7 | 2008-10-01 | 2014-09-15 |
| Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL Glucarpidase - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Nordic Society for Pediatric Hematology and Oncology | 47 | 2008-07-01 | 2018-09-28 |
| Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma glucarpidase, leucovorin calcium, methotrexate - Chemotherapeutic Agent Toxicity, Lymphoma | Phase 1 / Phase 2 | Completed | University College, London | 4 | 2008-07-01 | 2014-01-27 |
| Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin - Osteosarcoma, Leukemia | Phase 1 | Completed | BTG International Inc. | 20 | 2008-05-01 | 2022-06-06 |
| Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? Glucarpidase, Methotrexate, Folinic Acid - Osteosarcoma, Spindle Cell Sarcoma of Bone | Phase 2 | Terminated | University College, London | 34 | 2007-07-01 | 2015-06-04 |
| Voraxaze for Delayed Methotrexate Clearance Voraxaze (Glucarpidase), Placebo - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2007-01-01 | 2012-12-06 |
| Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance glucarpidase (50 Units/kg) - Neoplasms | Phase 2 | Completed | BTG International Inc. | 2000-01-01 | 2014-09-11 | |
| Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate glucarpidase - Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific | Not applicable | Completed | National Cancer Institute (NCI) | 10 | 1993-11-01 | 2015-04-30 |
| Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity Voraxaze (glucarpidase) - Neoplasms | Approved for marketing | BTG International Inc. | 2014-01-17 |
Osteosarcoma (6) · Lymphoma (4) · Renal Insufficiency (3) · Drug-Related Side Effects and Adverse Reactions (2) · Hematologic Neoplasms (2) · Leukemia (2) · Lymphoma, Large B-Cell, Diffuse (2) · Mucositis (2) · Neoplasms (2) · Neurotoxicity Syndromes (2) · Acute Kidney Injury (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Water Intoxication (1)
BTG International Inc. (4) · University College, London (2) · Assistance Publique - Hôpitaux de Paris (1) · Fox Chase Cancer Center (1) · Fundacion CRIS de Investigación para Vencer el Cáncer (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Nordic Society for Pediatric Hematology and Oncology (1) · OHSU Knight Cancer Institute (1) · Protherics Medicines Development Limited (1)
United States (6) · France (2) · Spain (2) · United Kingdom (2) · Australia (1) · Canada (1) · Denmark (1) · Finland (1) · Germany (1) · Iceland (1) · Italy (1) · Norway (1) · Sweden (1) · Switzerland (1)
Adolfo De la Fuente, PD (1) · Andrew Saunders, MD (1) · Brigitte C. Widemann, MD (1) · Carmelo Rizzari, MD (1) · Christopher Ryan (1) · Jeremy Whelan, Professor (1) · Jesper Heldrup, M D (1) · Lauren Schaff, MD (1) · Paul Litka, MD (1) · Pete Anderson, MD, PhD (1) · Roderick Johnson, MD (1) · Saroj Vadhan-Raj, MD (1) · Suzanne Kincaid, CCRA (1) · Thiel Eckhard, Prof. Dr.med. (1)